Glycylpressin (Terlipressin)

Glycylpressin is indicated for several serious conditions where rapid reduction of portal pressure or systemic vasodilation is required, and it is administered under close medical supervision.

• Management of acute esophageal variceal bleeding.
• Treatment of hepatorenal syndrome in patients with advanced liver disease.
• Adjunctive therapy for septic shock refractory to standard vasopressors.
• Control of severe hypotension associated with distributive shock when other agents are insufficient.
• Support of hemodynamics in patients undergoing liver transplantation with portal hypertension.

The safety profile of Glycylpressin reflects its vasoconstrictive activity; side effects are reported across a range of frequencies.

Common

• Headache, usually mild and transient.
• Nausea or vomiting, occurring shortly after infusion.
• Transient elevation of systolic blood pressure.
• Peripheral coldness or mild ischemia of extremities.
• Flushing or erythema at the infusion site.

Serious

• Myocardial ischemia, presenting as chest pain or ECG changes.
• Cardiac arrhythmias, including tachyarrhythmias or bradyarrhythmias.
• Severe hypertension requiring pharmacologic intervention.
• Ischemic limb events, such as pain, pallor, or loss of pulses.
• Acute renal failure, manifested by rapid rise in serum creatinine.

When prescribing Glycylpressin, clinicians should consider several precautionary measures to minimize risk and ensure appropriate use.

• Assess cardiovascular status before initiation, especially a history of ischemic heart disease.
• Monitor blood pressure and heart rate continuously during infusion.
• Use caution in patients with renal impairment; adjust dosing as needed.
• Avoid use in uncontrolled hypertension or severe peripheral vascular disease.
• Evaluate for potential hypersensitivity to terlipressin or formulation components.
• Consider pregnancy status; limited data are available, and use only if benefits outweigh risks.

Glycylpressin may interact with other agents that affect vascular tone or renal function; awareness of these interactions helps guide safe co‑administration.

Avoid

• Concomitant use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive hypertension risk.
• Combination with vasodilators that may blunt therapeutic effect (e.g., nitroglycerin) unless closely monitored.

Use with caution

• Concurrent administration of nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) may increase risk of renal injury.
• Beta‑blockers may mask tachycardia response; monitor heart rate.
• Diuretics can exacerbate intravascular volume shifts; adjust fluid management accordingly.